Reviewing Artivion (NYSE:AORT) and Zimmer Biomet (NYSE:ZBH)

Artivion (NYSE:AORT – Get Free Report) and Zimmer Biomet (NYSE:ZBH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Risk & Volatility

Artivion has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Valuation & Earnings

This table compares Artivion and Zimmer Biomet”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Artivion $441.33 million 2.11 $9.77 million ($0.36) -53.09
Zimmer Biomet $8.23 billion 2.37 $705.20 million $3.95 26.12

Zimmer Biomet has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Artivion and Zimmer Biomet, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artivion 1 0 6 0 2.71
Zimmer Biomet 1 16 7 0 2.25

Artivion currently has a consensus price target of $39.00, suggesting a potential upside of 104.06%. Zimmer Biomet has a consensus price target of $112.74, suggesting a potential upside of 9.26%. Given Artivion’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Artivion is more favorable than Zimmer Biomet.

Profitability

This table compares Artivion and Zimmer Biomet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Artivion -3.65% 5.12% 2.36%
Zimmer Biomet 8.95% 13.02% 7.17%

Institutional and Insider Ownership

86.4% of Artivion shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Zimmer Biomet beats Artivion on 9 of the 14 factors compared between the two stocks.

About Artivion

(Get Free Report)

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.